title: Increased serum pepsinogen I and recurrence of duodenal ulcer.
abstract: To determine whether the serum pepsinogen I (PG I) level would be a suitable marker for selecting patients at risk for duodenal ulcer recurrence and, thus, would benefit from maintenance therapy, we treated duodenal ulcer patients with H2-receptor antagonists. After healing 140 ulcer patients we assessed the recurrence rate at 1 year with and without maintenance therapy. The annual recurrence rates in duodenal ulcer patients with hyper-PGI (95 ng/ml or more), with 66 ng/ml less than or equal to PGI less than 95 ng/ml, and with PGI less than 66 ng/ml were 87.0%, 27.3%, and 17.9%, respectively, when they did not receive maintenance therapy. In patients with hyper-PGI the recurrence rate was significantly lower in patients receiving maintenance therapy than in patients not receiving maintenance therapy, whereas in patients with PGI less than 66 ng/ml the recurrence rate was as low as 20% regardless of maintenance therapy. These results indicate that maintenance therapy with half the dose of H2-receptor antagonist is not required by patients with PGI less than 66 ng/ml, whereas those with hyper-PGI may be good candidates for long-term maintenance therapy.
authors.affiliation: First Dept. of Internal Medicine, Hiroshima University School of Medicine, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Sumii
authors.forename: A
authors.initials: A
authors.lastname: Inbe
authors.forename: N
authors.initials: N
authors.lastname: Uemura
authors.forename: M
authors.initials: M
authors.lastname: Kimura
authors.forename: K
authors.initials: K
authors.lastname: Haruma
authors.forename: M
authors.initials: M
authors.lastname: Yoshihara
authors.forename: H
authors.initials: H
authors.lastname: Teshima
authors.forename: G
authors.initials: G
authors.lastname: Kajiyama
authors.forename: A
authors.initials: A
authors.lastname: Miyoshi
mesh_terms: D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D004381:Duodenal Ulcer / Q000097:blood* / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010435:Pepsinogens / Q000097:blood*; D012008:Recurrence
chemical_list: D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D010435:Pepsinogens